1492 Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

1492 Capital Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-75,988	Closed	-$1.33M	–	95
2020 Q2	$1.33M	Buy	75,988 +36,997	+95%	+$724K	1.14%	29
2020 Q1	$637K	Buy	+38,991	New	+$805K	0.76%	44
2019 Q3	–	Sell	-130,219	Closed	-$1.71M	–	95
2019 Q2	$1.71M	Sell	130,219 -6,742	-5%	-$90.2K	1.6%	20
2019 Q1	$2.07M	Sell	136,961 -13,228	-9%	-$212K	1.76%	20
2018 Q4	$2.58M	Buy	+150,189	New	+$2.57M	2.31%	15

Other funds holding COLL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

1492 Capital Management's COLL Position: Q3 2020 in Review

1492 Capital Management sold out of Collegium Pharmaceutical (COLL) in Q3 2020, closing a stake of 75,988 shares — an estimated $1.33M sold.

1492 Capital Management first reported a position in COLL in Q4 2018 and held it in 5 quarters. The position peaked at $2.58M in Q4 2018. 140 funds tracked by Wall St. Rank hold COLL as of Q3 2020.

1492 Capital Management reported no remaining Collegium Pharmaceutical position as of Q3 2020 after selling out during the quarter.
1492 Capital Management sold 75,988 Collegium Pharmaceutical shares in Q3 2020, an estimated $1.33M.
1492 Capital Management first reported a position in Collegium Pharmaceutical in Q4 2018 and held it in 5 quarters.
1492 Capital Management's Collegium Pharmaceutical position peaked at $2.58M in Q4 2018.
140 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2020.

Based on 1492 Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.